Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $15.07 USD
Change Today +0.26 / 1.76%
Volume 679.8K
MNTA On Other Exchanges
As of 4:30 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Ganesh Venkataraman Kaundinya Ph.D.

Co-Founder, Chief Scientific Officer and Senior Vice President of Research, Momenta Pharmaceuticals Inc.
AgeTotal Calculated CompensationThis person is connected to 14 board members in 1 different organizations across 2 different industries.

See Board Relationships
As of Fiscal Year 2013


Dr. Ganesh Venkataraman Kaundinya, Ph.D. is a co-founder of Momenta Pharmaceuticals Inc., and has been its Chief Scientific Officer since September 2007 and its Senior Vice President of Research since April 2005. Dr. Venkataraman served as Vice President of Technology at Momenta Pharmaceuticals Inc. from August 2002 to April 2005. He served as the Director of Bioinformatics for the Consortium for Functional Glycomics from August 2000 to January 2003 to study the role ...

Read Full Background

Corporate Headquarters*

675 West Kendall Street
Cambridge, Massachusetts 02142

United States

Phone: 617-491-9700
Fax: 617-621-0431

Board Members Memberships*

There is no Board Members Memberships data available.


Massachusetts Institute of Technology
Massachusetts Institute of Technology

Other Affiliations*

Annual Compensation*

Total Annual Compensation$387,482

Stock Options*

Restricted Stock Awards$138,380
All Other Compensation$12,474
Exercisable Options182,723
Exercisable Options Value$1,415,697
Unexercisable Options47,080
Unexercisable Options Value$188,009
Total Value of Options$1,603,705
Total Number of Options229,803

Total Compensation*

Total Annual Cash Compensation$554,561
Total Short Term Compensation$387,482
Other Long Term Compensation$150,854
Total Calculated Compensation$894,787
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $15.07 USD +0.26


Friedhelm Blobel Ph.D.Chief Executive Officer, President, Executive Director and Member of Business Development Committee
SciClone Pharmaceuticals, Inc.
Douglas A. Michels Chief Executive Officer, President and Director
OraSure Technologies, Inc.
Peter S. Greenleaf Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee
Sucampo Pharmaceuticals, Inc.
Rajeev Nannapaneni Vice Chairman, Chief Executive Officer, Chief Operating Officer and Member of Allotment Committee
Natco Pharma Limited
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at